secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001570562-24-000114
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q2 revenue $66.9M (+36% YoY); raises FY2024 guidance to $260-270M; first positive non-GAAP operating income
--------------------------------------------------------------------------------

- Total net revenue of $66.9M for Q2 2024, up 36% YoY from $49.3M.
- GAAP operating loss improved to $7.7M; first positive non-GAAP operating income of $1.1M.
- Raised full-year 2024 net revenue guidance to $260M-$270M (top end 34% YoY growth).
- PMA submitted to FDA for Evolysse Lift and Smooth fillers; approval and launch expected H2 2025.
- Added 770 new customer accounts; total ~14,000 since launch; reorder rate ~70%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056224000114/0001570562-24-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056224000114/eols-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001570562-24-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer